Syndax Pharmaceuticals issues $250M in 2.25% convertible senior notes due 2031
What's the deal? Syndax Pharmaceuticals (NASDAQ: SNDX) has issued $250M in 2.25% convertible senior notes due 2031 through a private placement. The transaction closed on June 10, 2026, and is expected to generate roughly $243M in net proceeds after fees. J. Wood Capital AdvisorsDealroom has a profile for this one. Try Dealroom → LLC served as the sole placement agent.
The notes are senior unsecured obligations that pay interest semiannually, starting December 15, 2026, and mature on June 15, 2031. Holders can convert under certain conditions at an initial price of approximately $24.76 per share — a 35% premium over the stock's last reported sale price on June 3, 2026.
Syndax plans to use the proceeds for general corporate purposes, including working capital, R&D, commercialisation, and business development.
Why now? Biotech firms often tap convertible debt markets when equity valuations are volatile or when they need capital without heavy dilution upfront. The 35% conversion premium suggests Syndax is betting its share price will rise meaningfully before 2031, giving it access to cheaper financing than a traditional equity raise would provide today.
What could go wrong? Convertible notes carry risks on both sides. If Syndax's stock surges well past the conversion price, existing shareholders face significant dilution. If it doesn't, the company still owes $250M in principal plus interest — a substantial debt burden for a clinical-stage biotech.
The notes are also unregistered under the Securities Act and subject to resale restrictions, which limits liquidity for holders and could complicate future capital raises.
The signal: Syndax is classified as a late-stage company focused on developing HDAC inhibitors for solid and haematological tumours, meaning this $250M raise likely targets the expensive final stretch of clinical trials and early commercialisation. The choice of convertible debt over a traditional equity raise — placed through J. Wood Capital Advisors — suggests Syndax is seeking to preserve equity value while securing a runway long enough to reach revenue-generating milestones before the 2031 maturity date.
Read more: ainvest
